115 related articles for article (PubMed ID: 1453329)
1. Inhibition of HIV-1 RNA production by the diphtheria toxin-related IL-2 fusion proteins DAB486IL-2 and DAB389IL-2.
Zhang L; Waters C; Nichols J; Crumpacker C
J Acquir Immune Defic Syndr (1988); 1992 Dec; 5(12):1181-7. PubMed ID: 1453329
[TBL] [Abstract][Full Text] [Related]
2. The interleukin-2 fusion protein, DAB389IL-2, inhibits the development of infectious virus in human immunodeficiency virus type 1-infected human peripheral blood mononuclear cells.
Zhang LJ; Waters CA; Poisson LR; Estis LF; Crumpacker CS
J Infect Dis; 1997 Apr; 175(4):790-4. PubMed ID: 9086131
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein.
Grailer AP; Nichols JC; Strom TB; Sollinger HW; Burlingham WJ
Cell Immunol; 1991 Feb; 132(2):481-93. PubMed ID: 1988163
[TBL] [Abstract][Full Text] [Related]
4. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation.
Walz G; Zanker B; Brand K; Waters C; Genbauffe F; Zeldis JB; Murphy JR; Strom TB
Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9485-8. PubMed ID: 2594781
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes.
Bousvaros A; Stevens AC; Strom TB; Murphy J; Lamont JT
Dig Dis Sci; 1997 Jul; 42(7):1542-8. PubMed ID: 9246061
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-4 receptor expression by human B cells: functional analysis with a human interleukin-4 toxin, DAB389IL-4.
Jabara HH; Vercelli D; Schneider LC; Williams DP; Genbauffe FS; Poisson LR; Waters CA; Geha RS
J Allergy Clin Immunol; 1995 Apr; 95(4):893-900. PubMed ID: 7722171
[TBL] [Abstract][Full Text] [Related]
7. DAB
Bhopale MK; Hilliard B; Constantinescu CS; Phillips SM; Rostami A
Immunopharmacol Immunotoxicol; 2017 Dec; 39(6):318-329. PubMed ID: 28929835
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes.
Salard D; Kuzel TM; Samuelson E; Rosen S; Bakouche O
J Clin Immunol; 1998 May; 18(3):223-34. PubMed ID: 9624582
[TBL] [Abstract][Full Text] [Related]
9. An intact transmembrane helix 9 is essential for the efficient delivery of the diphtheria toxin catalytic domain to the cytosol of target cells.
vanderSpek J; Cassidy D; Genbauffe F; Huynh PD; Murphy JR
J Biol Chem; 1994 Aug; 269(34):21455-9. PubMed ID: 8063778
[TBL] [Abstract][Full Text] [Related]
10. DAB486IL-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 receptor-bearing human peripheral blood mononuclear cells.
Waters CA; Snider CE; Itoh K; Poisson L; Strom TB; Murphy JR; Nichols JC
Ann N Y Acad Sci; 1991 Dec; 636():403-5. PubMed ID: 1793228
[No Abstract] [Full Text] [Related]
11. An IL-2-toxin, DAB389IL-2, inhibits delayed-type hypersensitivity but enhances IgE antibody production.
Pullerits T; Lundin S; Dahlgren U; Telemo E; Hanson LA; Lötvall J
J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):843-9. PubMed ID: 10329818
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Foss FM
Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
[TBL] [Abstract][Full Text] [Related]
13. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis.
Sewell KL; Parker KC; Woodworth TG; Reuben J; Swartz W; Trentham DE
Arthritis Rheum; 1993 Sep; 36(9):1223-33. PubMed ID: 8216416
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein.
Bacha P; Williams DP; Waters C; Williams JM; Murphy JR; Strom TB
J Exp Med; 1988 Feb; 167(2):612-22. PubMed ID: 3126255
[TBL] [Abstract][Full Text] [Related]
15. Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2. I. Studies of in vitro and in vivo efficacy.
Ramadan MA; Gabr NS; Bacha P; Günzler V; Phillips SM
Cell Immunol; 1995 Dec; 166(2):217-26. PubMed ID: 7497523
[TBL] [Abstract][Full Text] [Related]
16. A kinetic analysis of the effects of interleukin-2 diphtheria toxin fusion protein upon activated T cells.
Walz G; Zanker B; Murphy JR; Strom TB
Transplantation; 1990 Jan; 49(1):198-201. PubMed ID: 2301012
[TBL] [Abstract][Full Text] [Related]
17. PHA induces IL-2 receptors on B-CLL cells and is a potential biological response modifier for the LIL-2-diphtheria toxin, DAB486IL-2.
Bulger K; Padua F; Duff R; Pihan G; Nichols J; Murphy J; McCaffrey R
Leuk Res; 1994 Feb; 18(2):119-22. PubMed ID: 8107488
[TBL] [Abstract][Full Text] [Related]
18. Targeting diphtheria toxin to growth factor receptors.
Murphy JR; vanderSpek JC
Semin Cancer Biol; 1995 Oct; 6(5):259-67. PubMed ID: 8562903
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy.
Tepler I; Schwartz G; Parker K; Charette J; Kadin ME; Woodworth TG; Schnipper LE
Cancer; 1994 Feb; 73(4):1276-85. PubMed ID: 8313331
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia.
Kiyokawa T; Shirono K; Hattori T; Nishimura H; Yamaguchi K; Nichols JC; Strom TB; Murphy JR; Takatsuki K
Cancer Res; 1989 Jul; 49(14):4042-6. PubMed ID: 2786749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
